Category Archives: Genetics

Seattle Genetics, Inc. ( SGEN ) and Takeda Pharmaceutical Company Limited ( TKPYY ) announced four-year overall survival data from a pivotal phase II study evaluating the efficacy and safety of Adcetris for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Adcetris showed durable, long-term responses in this treatment setting. At a median follow-up in the study at 46.3 months, the four-year survival rate was estimated to be 64% (median overall survival (OS) of 55.1 months) with progression-free survival (PFS) of 20 months. In other words, more than 60% of patients suffering from relapsed or refractory ALCL treated with Adcetris were alive at the fourth year of follow-up. One-third of all the patients treated in this study showed complete remission with no evidence of disease after a median follow-up of 46 months. The company stated that historical outcomes for patients suffering from relapsed T-cell lymphoma, including systemic ALCL have shown a median OS of 5.5 months with a median PFS of 3.1 months. Meanwhile, Seattle Genetics also announced detailed results from a randomized, double-blind, placebo-controlled phase III study (AETHERA) on Adcetris for the treatment of Hodgkin lymphoma patients with the risk of disease progression following autologous … Continue reading →

genetics, Incomplete Dominance, snapdragon examples By: BiologyVittles … Continue reading →

Let's Play The Sims 3 - Perfect Genetics Challenge - Episode 44 Origin ID - Llandros2012 My Sims 3 Page: http://mypage.thesims3.com/mypage/Llandros2012 My Blog: http://Llandros09.blogspot.com My Facebook: https://www.face... By: Llandros09 … Continue reading →

By RTT News, December 07, 2014, 12:17:00 PM EDT (RTTNews.com) - Seattle Genetics Inc ( SGEN ) and Takeda Pharmaceutical Co Ltd on Sunday announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma. At a median follow up of 46.3 months, the estimated four-year survival rate was 64 percent. The data were presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA, December 6-9, 2014. "Historical outcomes for patients with relapsed T-cell lymphoma, including systemic ALCL have been poor, with a median overall survival of 5.5 months and a median progression-free survival of 3.1 months. The four-year survival data from the pivotal trial in systemic ALCL demonstrate ADCETRIS' activity in the treatment of this disease, with an estimated four-year survival rate of 64 percent and a median progression-free survival of 20 months," said Clay Siegall, Chief Executive Officer of Seattle Genetics. "These encouraging data show durable, long-term responses in … Continue reading →

The Sims 4: Perfect Genetics Legacy [Part 5] Kaydence Moves In With this newfound romance that Marshall and Kaydence have, they had become an official couple. With them becoming a couple there was only one thing that it ... By: Connor K Games … Continue reading →

Mendelian genetics, sweet pea examples By: BiologyVittles … Continue reading →

Hog Blog Genetics Video #2 This video is about Snake Genetics. Dominant vs Recessive, Mitosis vs Meiosis. Simple Genetics. By: Hog Blog! … Continue reading →

Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF) Announce Merger Plan The Genetics Policy Institute (GPI), producer of the annual World Stem Cell Summit, and the Regenerative Medicine Foundation (RMF) have agreed to merge in order to leverage their resources... By: worldstemcell … Continue reading →

Updated with new information. SAN FRANCISCO (TheStreet) -- The use of Seattle Genetics' (SGEN) Adcetris as a maintenance therapy after a stem-cell transplant in "high risk" Hodgkin lymphoma patients led to a 20 percentage point improvement in relapse rates compared to a placebo after two years of follow-up, researchers reported Saturday. The new Adcetris data comes from a phase III study known as AETHERA, which is being presented in full at the American Society of Hematology annual meeting underway here. Next year, Seattle Genetics intends to seek approval from regulators to expand the use of Adcetris into a larger pool of Hodgkin lymphoma patients based on the AETHERA study results. Must Read: Jim Cramers 4 Best Stock Picks for the Health Care Sector See more here: Seattle Genetics Makes Case for Expanded Use of Adcetris as Lymphoma Maintenance Therapy … Continue reading →

By RTT News, December 06, 2014, 11:20:00 AM EDT (RTTNews.com) - Seattle Genetics, Inc. ( SGEN ) and Takeda Pharmaceutical Company Limited reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL. ADCETRIS has been approved in more than 45 countries for the treatment of relapsed or refractory HL and systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is currently not approved in the AETHERA treatment setting. The Phase 3 AETHERA trial was designed to evaluate the potential of single agent ADCETRIS to extend PFS post-ASCT in patients with HL who have at least one risk factor for progression. In addition to the primary endpoint of PFS, secondary endpoints included overall survival (OS), safety and tolerability. A total of 329 HL patients at risk of relapse were enrolled, including 165 on the ADCETRIS arm and 164 on the placebo arm. Patients received … Continue reading →